NCT02775500Active, not recruiting
Apremilast Pregnancy Exposure Registry
Apremilast Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Source: ClinicalTrials.gov · Last updated 28 Jan 2025
Brief summary (registry, in English)
The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 233 (actual)
- First submitted
- 26 Jan 2016
- Start date
- Nov 2014
- Primary completion date
- Dec 2024
- Lead sponsor
- University of California, San Diego
- Diseases
- Psoriasis, Psoriatic arthritis, Childhood cancers
- NCT number
- NCT02775500
What you commit to
- Study type: Observational
- Participants enrolled: 233
- From Nov 2014 to the primary completion date, Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Pregnant
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Diego Coordinator of this site? Confirm its status | La Jolla | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.